Emerging roles of thioredoxin cycle enzymes in the central nervous system
Authors:
- 9 January 2005
- journal article
- review article
- Published by Springer Nature in Cellular and Molecular Life Sciences
- Vol. 62 (10) , 1063-1080
Abstract
The thioredoxins (Trxs) constitute a family of enzymes which catalyze the reduction of protein disulfide bonds. Recent animal studies have revealed the importance of the Trx superfamily in various experimental systems. For example, the homozygous disruption of the genes encoding cytoplasmic (TRX1) or mitochondrial Trx (TRX2) in mice generates lethal embryonic phenotypes. In contrast, transgenic mice overexpressing TRX1 show an extended life span and are relatively resistant to ischemia- mediated brain damage. In addition to their capacity to detoxify peroxides in concert with peroxiredoxins and Trx reductases, Trx isozymes perform multiple redox signaling functions mediated by their specific interaction with various proteins, including redox-regulated kinases and transcription factors. Recent studies indicate that specific isoforms of Trx cycle enzymes, targeted to different cell compartments, are key regulators of fundamental processes, such as gene expression, cell growth and apoptosis. The present review is primarily focused on the emerging neuroprotective role of these proteins in the central nervous system.Keywords
This publication has 6 references indexed in Scilit:
- Prasugrel versus Clopidogrel in Patients with Acute Coronary SyndromesNew England Journal of Medicine, 2007
- The impact of hs C-reactive protein and other inflammatory biomarkers on long-term cardiovascular mortality in patients with acute coronary syndromesAtherosclerosis, 2007
- C-Terminal Provasopressin (Copeptin) as a Novel and Prognostic Marker in Acute Myocardial InfarctionCirculation, 2007
- Comparison of Fondaparinux and Enoxaparin in Acute Coronary SyndromesNew England Journal of Medicine, 2006
- Early intravenous then oral metoprolol in 45 852 patients with acute myocardial infarction: randomised placebo-controlled trialThe Lancet, 2005
- Timing of aspirin administration as a determinant of survival of patients with acute myocardial infarction treated with thrombolysisThe American Journal of Cardiology, 2002